VIENNA, Va.--(BUSINESS WIRE)--CEL-SCI Corporation (NYSE American: CVM) reported financial results for the fiscal year ended September 30, 2024, as well as key clinical and corporate developments.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback